Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 28 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors				Phase III, Phase II				06-2247 NCT00442533
	Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors				Phase II, Phase I				UCSF-04458 NCT00227617
	Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer				Phase II, Phase I				VU-VICC-GI-0622 VICC-GI-0622, 6980, NCI-6980, NCT00397384
	Evaluation of Single Session Stereotactic Body Radiotherapy				Phase II, Phase I				2005-0445 NCT00492817
	Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors				Phase II, Phase I				CTCT 06-11 NCT00493883
	Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)				Phase II, Phase I				ID02-446 NCT00508443
	Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer				Phase II				NCI-04-C-0273 NCI-6332, DELCATH-G990039, NCT00096083
	Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract				Phase II				ID02-523 NCT00353015
	Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors				Phase II				END0002 97273, END0002, NCT00398320, NCT00398320
	Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer				Phase II				MDA-2006-0077 MDACC 2006-0077, 7650, NCT00454363


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute